We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RBC and Key Organics Announce Drug Discovery Collaboration
News

RBC and Key Organics Announce Drug Discovery Collaboration

RBC and Key Organics Announce Drug Discovery Collaboration
News

RBC and Key Organics Announce Drug Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RBC and Key Organics Announce Drug Discovery Collaboration "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Reaction Biology Corporation ("RBC") and Key Organics Ltd.  have announced that they have created a Joint Venture ("JV") to engage in high throughput drug discovery.

The purpose of the JV is to identify a series of compounds with the potential of becoming drugs with further research, and then to partner or sell the compounds to pharmaceutical companies interested in the selected targets.

Key Organics supplies diverse sets of compounds synthesized in-house using classical organic procedures optimized for primary screening of druggable targets.

RBC's DiscoveryDot™ microarray technology is designed to reduce screening volumes to one nanoliter size, allowing large scale screening.

Key Organics will provide compounds for screening against these targets using RBC's DiscoveryDot™ screening technology.

Key Organics will then provide additional chemical analysis and compound synthesis, and RBC will perform additional screening and profiling. The companies will then collaborate on further development of selected compounds.

Advertisement